Abrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Saba Capital Management, L.P. Sells 15,143 Shares

Abrdn Life Sciences Investors (NYSE:HQL) major shareholder Saba Capital Management, L.P. sold 15,143 shares of the stock in a transaction on Friday, January 31st. The shares were sold at an average price of $14.27, for a total value of $216,090.61. Following the sale, the insider now owns 3,381,371 shares of the company’s stock, valued at $48,252,164.17. This trade represents a 0.45 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Saba Capital Management, L.P. also recently made the following trade(s):

• On Wednesday, January 29th, Saba Capital Management, L.P. sold 11,674 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $14.12, for a total value of $164,836.88.

Abrdn Life Sciences Investors Price Performance

NYSE HQL traded down $0.21 on Monday, hitting $14.01. 170,163 shares of the company were exchanged, compared to its average volume of 115,032. Abrdn Life Sciences Investors has a twelve month low of $12.76 and a twelve month high of $15.90. The company’s 50 day moving average price is $13.77 and its 200-day moving average price is $14.59.

Abrdn Life Sciences Investors Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 10th. Investors of record on Thursday, November 21st were paid a $0.50 dividend. This is a positive change from Abrdn Life Sciences Investors’s previous quarterly dividend of $0.49. The ex-dividend date was Thursday, November 21st. This represents a $2.00 dividend on an annualized basis and a yield of 14.28%.

Institutional Trading of Abrdn Life Sciences Investors

Several large investors have recently added to or reduced their stakes in HQL. Future Financial Wealth Managment LLC purchased a new position in shares of Abrdn Life Sciences Investors during the third quarter valued at $30,000. Ashton Thomas Securities LLC purchased a new position in Abrdn Life Sciences Investors during the 3rd quarter valued at about $148,000. Kapstone Financial Advisors LLC purchased a new stake in shares of Abrdn Life Sciences Investors in the third quarter worth approximately $177,000. Sanctuary Advisors LLC acquired a new stake in shares of Abrdn Life Sciences Investors during the second quarter worth approximately $154,000. Finally, Kingswood Wealth Advisors LLC acquired a new stake in shares of Abrdn Life Sciences Investors during the fourth quarter worth approximately $160,000. 32.21% of the stock is owned by institutional investors and hedge funds.

About Abrdn Life Sciences Investors

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.